Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Guillermo Garcia Manero, MD, Luger Selina, MD, Klimek Virginia, MD, Cooper Maureen, MD, Emmanuel C. Besa, MD, James M. Rossetti, DO, Richard Chao, MD, Rachel Humphrey, Lewis R. Silverman, MD

Blood (2013) 122 (21): 1550.

https://doi.org/10.1182/blood.V122.21.1550.1550

Published: 2013

Journal Articles

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Blood (2012) 120 (21): 143.

https://doi.org/10.1182/blood.V120.21.143.143

Published: 2012

Journal Articles

The Use of Infliximab to Control Recurrent Cytokine Storms in EBV-Associated Angioimmunoblastic Lymphoma and Hemophagocytic Syndrome

Sameh Gaballa, MD, Emmanuel C. Besa, MD, Onder Alpdogan, MD

Blood (2012) 120 (21): 4887.

https://doi.org/10.1182/blood.V120.21.4887.4887

Published: 2012

Journal Articles

A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients

Philip A. Pancari, MD, Emmanuel C. Besa, MD, Jackie Quan, Amanda Padula, Erev E. Tubb, MD, Raymond Vvacqua

Blood (2012) 120 (21): 4942.

https://doi.org/10.1182/blood.V120.21.4942.4942

Published: 2012

Journal Articles

Maintenance Low Dose 13 Cis-Retinoic Acid and Alpha Tocopherol Improves Survival Compared to High Dose Therapy for 6 Months In LOW and INT-1/2 Stage MDS: Role for Prevention Trial

Emmanuel C. Besa, Professor of Medical Oncology, Joseph Vadakara, Fellow, Physician

Blood (2011) 118 (21): 5053.

https://doi.org/10.1182/blood.V118.21.5053.5053

Published: 2011

Journal Articles

Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/ Refractory Acute Leukemias

Joanne Filicko-O'Hara, MD, Bijoyesh Mookerjee, MBBS, Onder Alpdogan, MD, Emmanuel C. Besa, MD, Matthew Carabasi, MD, Elena Gitelson, MD, Margaret Kasner, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD

Blood (2010) 116 (21): 2192.

https://doi.org/10.1182/blood.V116.21.2192.2192

Published: 2010

Journal Articles

Haploidentical Transplantation In Adults ≥ 66 Years of Age

Dolores Grosso, DNP, Onder Alpdogan, MD, Emmanuel C. Besa, MD, Matthew Carabasi, MD, Beth Colombe, PhD, Patricia Cornett Farley, BSc, Joanne Filicko-O'Hara, MD, Elena Gitelson, MD, Margaret Kasner, MD, Ubaldo Martinez-Outshoorn, MD, William O'Hara, PharmD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD

Blood (2010) 116 (21): 3529.

https://doi.org/10.1182/blood.V116.21.3529.3529

Published: 2010

Journal Articles

HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease

Maria M. Sbenghe, MD, Amit Mahipal, MBBS, MPH, Alina Dulau Florea, Emmanuel C. Besa, MD, Paul Bray, MD, Jaime Caro, MD

Blood (2010) 116 (21): 4897.

https://doi.org/10.1182/blood.V116.21.4897.4897

Published: 2010

Journal Articles

Nonanthracycline Induction Chemotherapy (T-FLAG) for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Amit Mahipal, MBBS, MPH, Emmanuel C. Besa, MD, Anne Marie Valorie-Oberlie, Pharmacist, Specialist-Oncology, Isaac Matthias, Medical, Student, Adam Thode, Medical, Student

Blood (2010) 116 (21): 4356.

https://doi.org/10.1182/blood.V116.21.4356.4356

Published: 2010

Journal Articles

Immunomodulatory Therapy with Combination of Low Dose Thalidomide, Alpha Interferon (IFN-a) and Prednisone Produces Durable Response In Myelofibrosis

Shilpa Gupta, MD, Emmanuel C. Besa

Blood (2010) 116 (21): 4123.

https://doi.org/10.1182/blood.V116.21.4123.4123

Published: 2010

Journal Articles

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Alan F. List, Maria R. Baer, David P. Steensma, Azra Raza, Jason Esposito, Noelia Martinez-Lopez, Carole Paley, John Feigert, Emmanuel C. Besa

Blood (2009) 114 (22): 3829.

https://doi.org/10.1182/blood.V114.22.3829.3829

Published: 2009

Journal Articles

Iron Chelation with Deferasirox (Exjade ® ) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Alan F List, Maria R Baer, David Steensma, Azra Raza, Jason Esposito, Jodi Virkus, Carole Paley, John Feigert, Emmanuel C Besa

Blood (2008) 112 (11): 634.

https://doi.org/10.1182/blood.V112.11.634.634

Published: 2008

Journal Articles

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS).

Erev E. Tubb, MD, Emmanuel C. Besa, MD, Aristoteles Giagounidis, MD, Gustavo A. Fonseca, MD

Blood (2007) 110 (11): 1447.

https://doi.org/10.1182/blood.V110.11.1447.1447

Published: 2007

Journal Articles

Additon of Low-Dose Interferon-alpha (LD-IFN-a) and Lenalidomide after Failure to a Combination of Thalidomide and Prednisone in Myelofibrosis with Myeloid Metaplasia (MMM).

Lisa Reale, MD, Emmanuel C. Besa, M.D.

Blood (2007) 110 (11): 4645.

https://doi.org/10.1182/blood.V110.11.4645.4645

Published: 2007

Journal Articles

Rituximab Use in Four Patients with Acquired vonWillebrand’s Syndrome.

Priya C. Singh, MD, Jamie E. Siegel, MD, Jaime Caro, MD, Emmanuel C. Besa

Blood (2006) 108 (11): 4045.

https://doi.org/10.1182/blood.V108.11.4045.4045

Published: 2006

Journal Articles

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Emmanuel C. Besa, MD, Vanlila Swami, MD, Paul Roda, M.D, Mary Ann Laudadio, R.N., Robert Knight, MD, Jerome Zeldis, MD

Blood (2005) 106 (11): 4908.

https://doi.org/10.1182/blood.V106.11.4908.4908

Published: 2005

NARROW

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

The Use of Infliximab to Control Recurrent Cytokine Storms in EBV-Associated Angioimmunoblastic Lymphoma and Hemophagocytic Syndrome

A Proposed Steroid Mobilization Test to Separate Margination From Marrow Suppression and to Determine Drug Cessation for Safety in Lenalidomide-Induced Neutropenia in Non-Del(5q) MDS Low and INT-1 Patients

Maintenance Low Dose 13 Cis-Retinoic Acid and Alpha Tocopherol Improves Survival Compared to High Dose Therapy for 6 Months In LOW and INT-1/2 Stage MDS: Role for Prevention Trial

Phase II Study of Bortezomib, Mitoxantrone and Etoposide In Relapsed/ Refractory Acute Leukemias

Haploidentical Transplantation In Adults ≥ 66 Years of Age

HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease

Nonanthracycline Induction Chemotherapy (T-FLAG) for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Immunomodulatory Therapy with Combination of Low Dose Thalidomide, Alpha Interferon (IFN-a) and Prednisone Produces Durable Response In Myelofibrosis

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Iron Chelation with Deferasirox (Exjade ® ) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS).

Additon of Low-Dose Interferon-alpha (LD-IFN-a) and Lenalidomide after Failure to a Combination of Thalidomide and Prednisone in Myelofibrosis with Myeloid Metaplasia (MMM).

Rituximab Use in Four Patients with Acquired vonWillebrand’s Syndrome.

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only